Multiple sclerosis
- PMID: 11955556
- DOI: 10.1016/S0140-6736(02)08220-X
Multiple sclerosis
Erratum in
- Lancet 2002 Aug 24;360(9333):648
Abstract
Multiple sclerosis is the prototype inflammatory autoimmune disorder of the central nervous system and, with a lifetime risk of one in 400, potentially the most common cause of neurological disability in young adults. As with all complex traits, the disorder results from an interplay between as yet unidentified environmental factors and susceptibility genes. Together, these factors trigger a cascade of events, involving engagement of the immune system, acute inflammatory injury of axons and glia, recovery of function and structural repair, post-inflammatory gliosis, and neurodegeneration. The sequential involvement of these processes underlies the clinical course characterised by episodes with recovery, episodes leaving persistent deficits, and secondary progression. The aim of treatment is to reduce the frequency, and limit the lasting effects, of relapses, relieve symptoms, prevent disability arising from disease progression, and promote tissue repair. Despite limited success in each of these categories, everyone touched by multiple sclerosis looks for a better dividend from applying an improved understanding of the pathogenesis to clinical management.
Similar articles
-
Interferon-beta1a treatment for multiple sclerosis.Expert Rev Neurother. 2005 Jan;5(1):25-34. doi: 10.1586/14737175.5.1.25. Expert Rev Neurother. 2005. PMID: 15853471 Review.
-
Neuronal injury in chronic CNS inflammation.Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):551-62. doi: 10.1016/j.bpa.2010.11.001. Epub 2010 Nov 29. Best Pract Res Clin Anaesthesiol. 2010. PMID: 21619866 Review.
-
New options for early treatment of multiple sclerosis.J Neurol Sci. 2009 Feb 1;277 Suppl 1:S9-S11. doi: 10.1016/S0022-510X(09)70004-8. J Neurol Sci. 2009. PMID: 19200870 Review.
-
[New approaches in research of therapy of multiple sclerosis].Med Klin (Munich). 2001 Sep 15;96 Suppl 1:23-8. Med Klin (Munich). 2001. PMID: 11603112 German.
-
Immune regulation of multiple sclerosis.Handb Clin Neurol. 2014;122:3-14. doi: 10.1016/B978-0-444-52001-2.00001-7. Handb Clin Neurol. 2014. PMID: 24507511 Review.
Cited by
-
Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.Cochrane Database Syst Rev. 2024 Sep 10;9(9):CD015443. doi: 10.1002/14651858.CD015443.pub2. Cochrane Database Syst Rev. 2024. PMID: 39254048 Free PMC article.
-
Loss of miR-145 promotes remyelination and functional recovery in a model of chronic central demyelination.Commun Biol. 2024 Jul 4;7(1):813. doi: 10.1038/s42003-024-06513-x. Commun Biol. 2024. PMID: 38965401 Free PMC article.
-
Abnormal eye movements increase as motor disabilities and cognitive impairments become more evident in Multiple Sclerosis: A novel eye-tracking study.Mult Scler J Exp Transl Clin. 2024 May 29;10(2):20552173241255008. doi: 10.1177/20552173241255008. eCollection 2024 Apr-Jun. Mult Scler J Exp Transl Clin. 2024. PMID: 38817553 Free PMC article.
-
Dietary Inflammatory Index score and its association with body mass index, body fat percentage, body fat mass, and lipid profile in patients with multiple sclerosis.Turk J Med Sci. 2023 Jun 21;53(5):1155-1165. doi: 10.55730/1300-0144.5681. eCollection 2023. Turk J Med Sci. 2023. PMID: 38813018 Free PMC article.
-
Establishment of a high-content compatible platform to assess effects of monocyte-derived factors on neural stem cell proliferation and differentiation.Sci Rep. 2024 May 28;14(1):12167. doi: 10.1038/s41598-024-57066-2. Sci Rep. 2024. PMID: 38806485 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials